Todd E. Simpson - 08 Jun 2023 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)

Reporting relationship: Director
Issuer ticker: NGNE
Reported as of: 08 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2023, 16:28:18 UTC
Prior SEC filing: 12 Apr 2023
Next SEC filing: 17 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Sean Smith, Attorney-in-Fact for Todd E. Simpson

Key filing fact

Todd E. Simpson filed Form 4 for Neoleukin Therapeutics, Inc. (NGNE) on 09 Jun 2023.

Key facts

This page summarizes Todd E. Simpson's Form 4 filing for Neoleukin Therapeutics, Inc. (NGNE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2023, 16:28.

Change

Previous filing in this sequence was filed on 12 Apr 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NLTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 08 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $0.7900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.